Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

NCT03222167 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Chronic Hepatitis C Genotype 1B
Metabolic Syndrome
Fibrosis, Liver
Cirrhoses, Liver

Interventions

DRUG: Elbasvir/ Grazoprevir 50/100 mg fixed dose combination

Sponsor

Institute Of Cardiology & Internal Diseases, Kazakhstan

Collaborators

[object Object]
[object Object]